What is the implantation dip and does urinary estrone‑3‑glucuronide (E1G) decrease during implantation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

The Implantation Dip

The "implantation dip" is not a validated clinical phenomenon and does not represent a reliable marker of implantation timing or success. While some fertility tracking literature has described a transient drop in basal body temperature around the time of presumed implantation, this observation lacks scientific validation and should not be used for clinical decision-making.

What Actually Happens During Implantation

Estrogen levels do not consistently dip during implantation. Instead, estrogen plays a critical regulatory role in establishing and maintaining the window of uterine receptivity:

  • Estrogen within a narrow physiological range determines the duration of the window of uterine receptivity, with lower estrogen levels keeping the window open longer and higher levels causing it to close more rapidly 1
  • Implantation in mammals (including giant pandas with delayed implantation) is associated with rising pregnanediol glucuronide (PdG) levels, not estrogen dips—PdG increases from baseline to 60-80 ng/mg creatinine coincident with implantation 2
  • Urinary estrone-3-glucuronide (E1G) primarily reflects follicular growth, with peak E1G occurring pre-ovulation; post-ovulatory E1G patterns are variable and do not show a consistent "dip" at implantation 3, 4

Hormonal Patterns Around Implantation

The actual hormonal signature of implantation involves progesterone metabolites, not estrogen dips:

  • Pregnanediol glucuronide (PdG) rises after ovulation from less than 5 ng/mg creatinine to 15-30 ng/mg creatinine, then shows further increases (to 60-80 ng/mg creatinine) approximately 114 days after mating in species with delayed implantation, presumably coincident with implantation 2
  • E1G excretion rates provide direct measurement of follicular growth but do not reliably indicate implantation timing 3
  • Estrogen and progesterone together regulate endometrial receptivity through complex molecular mediators including pinopodes, cell adhesion molecules, cytokines, and growth factors 5

Clinical Implications

Do not rely on temperature or hormone "dips" to diagnose or time implantation:

  • The window of uterine receptivity is regulated by precise estrogen levels within a narrow range, not by transient dips 1
  • Elevated estrogen levels (as seen with controlled ovarian hyperstimulation) can have detrimental effects on the endometrium and implantation success 5
  • Monitoring E1G and PdG excretion rates can help navigate ovarian activity patterns (anovulatory vs. ovulatory cycles, luteal phase adequacy), but these do not show consistent "dips" at implantation 3

Common Pitfalls to Avoid

  • Do not interpret random temperature fluctuations as implantation markers—these lack scientific validation and can lead to false reassurance or unnecessary anxiety
  • Do not expect E1G to show a consistent pattern during the luteal phase—E1G primarily reflects follicular activity, and post-ovulatory patterns are highly variable 4
  • Do not confuse the post-ovulatory PdG rise with implantation timing—the initial PdG rise reflects corpus luteum function after ovulation, not implantation itself 2, 3

Related Questions

Is a one-day dip in estradiol (E2) levels during the implantation window normal in a woman undergoing fertility treatment, particularly in those with a history of infertility or previous unsuccessful implantations?
I am a woman of reproductive age using a urinary fertility monitor; based on my estrone‑3‑glucuronide (E1G), luteinising hormone (LH) and pregnanediol‑glucuronide (PDG) trends showing an LH surge peaking at 45 IU on cycle day 13 and still elevated on day 14, did I ovulate, and if so on which day? When should I begin progesterone supplementation for possible luteal phase insufficiency, and until when is the oocyte viable? Will intercourse on the evening of cycle day 15 still be within the fertile window?
Based on my hormone trends (luteinizing hormone surge, estrone‑3‑glucuronide and pregnanediol‑glucuronide levels) and cramps on cycle day 15, did I ovulate, on which cycle day did ovulation occur, when should I start progesterone therapy for luteal phase insufficiency, and how long does the released oocyte remain viable for fertilization (e.g., through late cycle day 15 or day 16)?
Is my estrone‑glucuronide (E1G) level of 43.8 µg on cycle day 20 (seven days after the LH surge) appropriate for early pregnancy while I am receiving progesterone supplementation?
I am on cycle day 14 with an LH peak of 45 IU, estrone‑3‑glucuronide peak, PDG rise to 4.7 µg/mL, and a brief pelvic pressure at 5:50 pm; did I ovulate, when did it occur, when should I start progesterone for luteal‑phase insufficiency, and how long is the oocyte viable after ovulation?
What is the significance of a white blood cell count of 11.4 × 10⁹/L in an adult?
What is the appropriate amoxicillin‑clavulanate (Clavulin) dosing regimen and duration for acute streptococcal pharyngitis in adults and children?
How should a 7.4 mm simple breast cyst be managed?
How should I begin the workup of an isolated triglyceride level of 350 mg/dL?
Which supplement is recommended for muscle hypertrophy?
Is calcifediol (25‑hydroxyvitamin D3) FDA‑approved for use in pregnancy, and is it safe to prescribe to pregnant patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.